Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates

EMERYVILLE, Calif.--(BUSINESS WIRE)--Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including lead asset NPM-119 for the treatment of patients with type 2 diabetes, today announced financial results for the third quarter ending September 30, 2022 and provides business updates. Recent Business Highlights The merger of Second Sight Medical Products, Inc. and Nano Precision Medical, Inc. closed on August